This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    NRG BN-001
Previous Study | Return to List | Next Study

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2017 by NRG Oncology
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Radiation Therapy Oncology Group
Information provided by (Responsible Party):
NRG Oncology
ClinicalTrials.gov Identifier:
NCT02179086
First received: June 27, 2014
Last updated: September 6, 2017
Last verified: September 2017
  Purpose
This randomized phase II trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as temozolomide, may make tumor cells more sensitive to radiation therapy. It is not yet known whether dose-escalated photon IMRT or proton beam radiation therapy is more effective than standard-dose radiation therapy with temozolomide in treating glioblastoma.

Condition Intervention Phase
Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Radiation: 3-dimensional conformal radiation therapy Radiation: intensity-modulated radiation therapy Radiation: photon beam radiation therapy Radiation: proton beam radiation therapy Drug: temozolomide Other: laboratory biomarker analysis Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma

Resource links provided by NLM:


Further study details as provided by NRG Oncology:

Primary Outcome Measures:
  • Overall survival (OS) compared between dose-escalated and -intensified photon IMRT or proton beam therapy with concomitant and adjuvant temozolomide and the standard-dose photon irradiation with concomitant and adjuvant temozolomide [ Time Frame: Date of randomization to the date of death due to any cause, assessed up to 5 years ]
    OS rate will be estimated using the Kaplan-Meier method, and differences between treatment arms will be tested in a stratified log-rank test, consistent with the stratified randomization. The OS rates by MGMT, recursive partitioning analysis (RPA) class and other prognostic factors will be estimated by Kaplan-Meier methods and compared using the log-rank test. Multivariate analyses with the Cox proportional hazard model for OS will be performed to assess the treatment effect adjusting for patient-specific risk factors.


Secondary Outcome Measures:
  • OS when compared between dose-escalated and -intensified photon IMRT to dose-escalated and -intensified proton beam therapy [ Time Frame: Date of randomization to the date of death, assessed up to 5 years ]
    If the instrumental variable assumptions hold, OS rate will be estimated using the Kaplan-Meier method, and differences between treatment arms will be tested in the log-rank test.

  • Progression-free survival (PFS) [ Time Frame: Date of randomization to the date of progression or death, assessed up to 5 years ]
    PFS rates will be estimated using the Kaplan-Meier method and comparisons between treatment arms will be made in the same manner as for OS.

  • Incidence of treatment-related toxicity, as measured by the Common Terminology Criteria for Adverse Events version 4 [ Time Frame: Up to 5 years ]
    Differences in observed severities of toxicities (grade 3+) between groups will be estimated using an exact binomial distribution together with 95% confidence interval. The difference between the 2 groups will be tested using a chi square test. If the instrumental variable assumptions hold the experimental arms will also be compared.

  • Change in perceived cognitive function, as measured by M.D. Anderson Symptom Inventory Brain Tumor [ Time Frame: Baseline to up to 60 weeks ]
    The change from baseline to each follow-up time point for the perceived cognitive symptom severity score will each be compared using a t-test with alpha=0.05, or Wilcoxon test if the data is not normally distributed, between treatment arms within each group. If the instrumental variable assumptions hold and the perceived cognitive function is significantly different within both groups, a test will be performed to compare between the 2 experimental arms.

  • Change in neurocognitive function, as measured by Hopkins' Verbal Learning Test-Revised, Trail Making Test Parts A and B, and Controlled Oral Word Association Test [ Time Frame: Baseline to up to 60 weeks ]
    The change from baseline to each follow-up time point for the perceived Clinical Trial Battery (CTB) composite score will each be compared using a t-test with alpha=0.05, or Wilcoxon test if the data is not normally distributed, between treatment arms within each group. If the instrumental variable assumptions hold and the CTB composite score is significantly different within both groups, a test will be performed to compare between the 2 experimental arms.

  • Change in CD4 lymphopenia count [ Time Frame: Baseline to up to 5 years ]
    The change from baseline to the completion of radiation will be compared between the control and experimental arms in each group using a t-test. If the instrumental variable assumptions hold, then it will be compared between the experimental arms. A repeated measures analysis, using a mixed effects model, will be used to assess the change of CD4 lymphopenia across time. CD4 count at 2 months after beginning therapy (dichotomized at 200) was shown to be prognostic of OS. This will be assessed here based on the CD4 count at the completion of chemoradiation which matches best to 2-months.

  • Use of magnetic resonance diffusion and perfusion imaging to differentiate between tumor progression and pseudo-progression [ Time Frame: Up to 5 years ]
    Retrospective analysis will be performed to evaluate and refine the method and the threshold cut-off point determined from our previous single institute data set to determine progression using the first one-third of the patient data collected in this trial. If the initial analysis supports our preliminary results with sufficient high sensitivity and specificity, e.g., 80% specificity and 90% sensitivity or higher, results will be validated using the remaining two-thirds of the imaging data.


Estimated Enrollment: 606
Actual Study Start Date: October 27, 2014
Estimated Study Completion Date: May 2024
Estimated Primary Completion Date: May 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm A1 (control)

Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT QD, 5 days a week for 23 fractions plus a boost of 7 additional fractions.

In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Radiation: 3-dimensional conformal radiation therapy
Undergo standard-dose 3D-CRT
Other Names:
  • 3D conformal radiation therapy
  • 3D-CRT
Radiation: intensity-modulated radiation therapy
Undergo standard-dose IMRT
Other Name: IMRT
Drug: temozolomide
Given PO
Other Names:
  • SCH 52365
  • Temodal
  • Temodar
  • TMZ
Other: laboratory biomarker analysis
Correlative studies
Experimental: Arm B (photon IMRT)

Patients undergo dose-escalated and -intensified photon IMRT QD, 5 days a week for a total of 30 fractions.

In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Radiation: photon beam radiation therapy
Undergo dose-escalated and -intensified photon IMRT
Radiation: intensity-modulated radiation therapy
Undergo dose-escalated and -intensified photon IMRT
Other Name: IMRT
Drug: temozolomide
Given PO
Other Names:
  • SCH 52365
  • Temodal
  • Temodar
  • TMZ
Other: laboratory biomarker analysis
Correlative studies
Active Comparator: Arm A2 (control)

Patients undergo standard-dose photon irradiation using 3D-CRT or IMRT as in Arm A1.

In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Radiation: 3-dimensional conformal radiation therapy
Undergo standard-dose 3D-CRT
Other Names:
  • 3D conformal radiation therapy
  • 3D-CRT
Radiation: intensity-modulated radiation therapy
Undergo standard-dose IMRT
Other Name: IMRT
Drug: temozolomide
Given PO
Other Names:
  • SCH 52365
  • Temodal
  • Temodar
  • TMZ
Other: laboratory biomarker analysis
Correlative studies
Experimental: Arm C (proton beam radiation therapy)

Patients undergo dose-escalated and -intensified proton beam therapy QD, 5 days a week for a total of 30 fractions.

In all treatment arms, patients receive temozolomide PO QD on days 1-49 of radiation therapy. Beginning 4 weeks later, patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Radiation: proton beam radiation therapy
Undergo dose-escalated and -intensified proton beam radiation therapy
Drug: temozolomide
Given PO
Other Names:
  • SCH 52365
  • Temodal
  • Temodar
  • TMZ
Other: laboratory biomarker analysis
Correlative studies

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • PRIOR TO STEP 1 REGISTRATION
  • A diagnostic contrast-enhanced magnetic resonance imaging (MRI) (no other scan type allowed) of the brain must be performed postoperatively within 72 hours of resection; the enhancing tumor must have a maximal diameter of 5 cm; the tumor diameter will be the greatest diameter as measured on the contrast-enhanced postoperative MRI and will include residual disease and/or the postoperative surgical cavity as appropriate; for cases where residual disease or postoperative surgical cavity is NOT identifiable (e.g., polar glioblastomas [GBMs] where a polar lobectomy is performed), the patient will be excluded from the trial
  • The GBM tumor must be located in the supratentorial compartment only (any component involving the brain stem or cerebellum is not allowed)
  • Patients must provide study-specific informed consent prior to step 1 registration
  • PRIOR TO STEP 2 REGISTRATION
  • Histologically proven diagnosis of glioblastoma (World Health Organization [WHO] grade IV) confirmed by central review prior to step 2 registration
  • Tumor tissue that is determined by central pathology review prior to step 2 registration to be of sufficient quantity for analysis of O6-methylguanin-DNA-methyltransferase (MGMT) status

    • Patients must have at least 1 block of tumor tissue; submission of 2 blocks is strongly encouraged to maximize the chances of eligibility; at least 1 cubic centimeter of tissue composed primarily of tumor must be present
    • Diagnosis must be made by surgical excision, either partial or complete; stereotactic biopsy or cavitron ultrasonic suction aspirator (CUSA) technique are not allowed
  • History/physical examination within 28 days prior to step 2 registration
  • The patient must have recovered from effects of surgery, postoperative infection, and other complications within 28 days prior to step 2 registration
  • Documentation of steroid doses within 28 days prior to step 2 registration
  • Karnofsky performance status >= 70 within 28 days prior to step 2 registration
  • Age >= 18
  • Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
  • Platelets >= 100,000 cells/mm^3
  • Hemoglobin >= 10.0 g/dl (note: the use of transfusion or other intervention to achieve hemoglobin (Hgb) >= 10.0 g/dl is acceptable)
  • Bilirubin =< 1.5 upper limit of normal (ULN)
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
  • Negative serum pregnancy test obtained for females of child-bearing potential within 28 days prior to step 2 registration

Exclusion Criteria:

  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 3 years; (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
  • Recurrent or multifocal malignant gliomas
  • Any site of distant disease (for example, drop metastases from the GBM tumor site)
  • Prior chemotherapy or radiosensitizers for cancers of the head and neck region; note that prior chemotherapy for a different cancer is allowable (except temozolomide)
  • Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment are not permitted
  • Prior radiotherapy to the head or neck (except for T1 glottic cancer), resulting in overlap of radiation fields
  • Severe, active co-morbidity, defined as follows:

    • Unstable angina at step 2 registration
    • Transmural myocardial infarction within the last 6 months prior to step 2 registration
    • Evidence of recent myocardial infarction or ischemia by the findings of S-T elevations of >= 2 mm using the analysis of an electrocardiogram (EKG) performed within 28 days prior to step 2 registration
    • New York Heart Association grade II or greater congestive heart failure requiring hospitalization within 12 months prior to step 2 registration
    • Serious and inadequately controlled arrhythmia at step 2 registration
    • Serious or non-healing wound, ulcer or bone fracture or history of abdominal fistula, intra-abdominal abscess requiring major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to step 2 registration, with the exception of the craniotomy for surgical resection
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step 2 registration
    • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol
    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of step 2 registration
    • Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol
    • Any other severe immunocompromised condition
    • Active connective tissue disorders, such as lupus or scleroderma, that in the opinion of the treating physician may put the patient at high risk for radiation toxicity
    • End-stage renal disease (ie, on dialysis or dialysis has been recommended)
    • Any other major medical illnesses or psychiatric treatments that in the investigator's opinion will prevent administration or completion of protocol therapy
  • Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
  • Patents treated on any other therapeutic clinical protocols within 30 days prior to step 2 registration
  • Inability to undergo MRI (e.g., due to safety reasons, such as presence of a pacemaker, or severe claustrophobia)
  • Postoperative tumor plus surgical bed size exceeds 5 cm in maximum diameter.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02179086

  Hide Study Locations
Locations
United States, Alabama
University of Alabama at Birmingham Cancer Center Suspended
Birmingham, Alabama, United States, 35233
United States, Arizona
Saint Joseph's Hospital and Medical Center Recruiting
Phoenix, Arizona, United States, 85013
Contact: David G. Brachman    800-360-6371      
Principal Investigator: David G. Brachman         
Arizona Oncology Associates-West Orange Grove Suspended
Tucson, Arizona, United States, 85704
The University of Arizona Medical Center-University Campus Recruiting
Tucson, Arizona, United States, 85724
Contact: Baldassarre Stea    520-626-9008      
Principal Investigator: Baldassarre Stea         
United States, Arkansas
University of Arkansas for Medical Sciences Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Sanjay Maraboyina    501-686-8274      
Principal Investigator: Sanjay Maraboyina         
United States, California
Sutter Cancer Centers Radiation Oncology Services-Auburn Recruiting
Auburn, California, United States, 95603
Contact: Christopher U. Jones    916-537-5237      
Principal Investigator: Christopher U. Jones         
AIS Cancer Center at San Joaquin Community Hospital Recruiting
Bakersfield, California, United States, 93301
Contact: Ruben C. Fragoso    916-734-3089      
Principal Investigator: Ruben C. Fragoso         
Alta Bates Summit Medical Center-Herrick Campus Recruiting
Berkeley, California, United States, 94704
Contact: Christopher U. Jones    916-537-5237      
Principal Investigator: Christopher U. Jones         
Sutter Cancer Centers Radiation Oncology Services-Cameron Park Recruiting
Cameron Park, California, United States, 95682
Contact: Christopher U. Jones    916-537-5237      
Principal Investigator: Christopher U. Jones         
Eden Hospital Medical Center Recruiting
Castro Valley, California, United States, 94546
Contact: Christopher U. Jones    916-537-5237      
Principal Investigator: Christopher U. Jones         
Loma Linda University Medical Center Recruiting
Loma Linda, California, United States, 92354
Contact: Joseph I. Kang    909-558-3375      
Principal Investigator: Joseph I. Kang         
Los Angeles County-USC Medical Center Recruiting
Los Angeles, California, United States, 90033
Contact: Richard L. Jennelle    323-865-0451      
Principal Investigator: Richard L. Jennelle         
USC / Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Richard L. Jennelle    323-865-0451      
Principal Investigator: Richard L. Jennelle         
Cedars Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact: Stephen L. Shiao    310-423-8965      
Principal Investigator: Stephen L. Shiao         
Fremont - Rideout Cancer Center Recruiting
Marysville, California, United States, 95901
Contact: Ruben C. Fragoso    916-734-3089      
Principal Investigator: Ruben C. Fragoso         
Kaiser Permanente Oakland-Broadway Recruiting
Oakland, California, United States, 94611
Contact: Samantha A. Seaward    877-827-3222      
Principal Investigator: Samantha A. Seaward         
Saint Joseph Hospital - Orange Suspended
Orange, California, United States, 92868
UC Irvine Health/Chao Family Comprehensive Cancer Center Recruiting
Orange, California, United States, 92868
Contact: Xiao-Tang Kong    877-827-8839    ucstudy@uci.edu   
Principal Investigator: Xiao-Tang Kong         
Palo Alto Medical Foundation Health Care Recruiting
Palo Alto, California, United States, 94301
Contact: Christopher U. Jones    916-537-5237      
Principal Investigator: Christopher U. Jones         
Pomona Valley Hospital Medical Center Recruiting
Pomona, California, United States, 91767
Contact: Yallapragada S. Rao    909-865-9555      
Principal Investigator: Yallapragada S. Rao         
Kaiser Permanente-Rancho Cordova Cancer Center Recruiting
Rancho Cordova, California, United States, 95670
Contact: Samantha A. Seaward    877-827-3222      
Principal Investigator: Samantha A. Seaward         
Rohnert Park Cancer Center Recruiting
Rohnert Park, California, United States, 94928
Contact: Samantha A. Seaward    877-827-3222      
Principal Investigator: Samantha A. Seaward         
Sutter Cancer Centers Radiation Oncology Services-Roseville Recruiting
Roseville, California, United States, 95661
Contact: Christopher U. Jones    916-537-5237      
Principal Investigator: Christopher U. Jones         
The Permanente Medical Group-Roseville Radiation Oncology Recruiting
Roseville, California, United States, 95678
Contact: Samantha A. Seaward    877-827-3222      
Principal Investigator: Samantha A. Seaward         
Sutter Medical Center Sacramento Recruiting
Sacramento, California, United States, 95816
Contact: Christopher U. Jones    916-537-5237      
Principal Investigator: Christopher U. Jones         
University of California Davis Comprehensive Cancer Center Recruiting
Sacramento, California, United States, 95817
Contact: Ruben C. Fragoso    916-734-3089      
Principal Investigator: Ruben C. Fragoso         
South Sacramento Cancer Center Recruiting
Sacramento, California, United States, 95823
Contact: Samantha A. Seaward    877-827-3222      
Principal Investigator: Samantha A. Seaward         
California Pacific Medical Center-Pacific Campus Recruiting
San Francisco, California, United States, 94115
Contact: Christopher U. Jones    916-537-5237      
Principal Investigator: Christopher U. Jones         
Palo Alto Medical Foundation-Santa Cruz Recruiting
Santa Cruz, California, United States, 95065
Contact: Christopher U. Jones    916-537-5237      
Principal Investigator: Christopher U. Jones         
Kaiser Permanente Cancer Treatment Center Recruiting
South San Francisco, California, United States, 94080
Contact: Samantha A. Seaward    877-827-3222      
Principal Investigator: Samantha A. Seaward         
Palo Alto Medical Foundation-Sunnyvale Recruiting
Sunnyvale, California, United States, 94086
Contact: Christopher U. Jones    916-537-5237      
Principal Investigator: Christopher U. Jones         
Sutter Cancer Centers Radiation Oncology Services-Vacaville Recruiting
Vacaville, California, United States, 95687
Contact: Christopher U. Jones    916-537-5237      
Principal Investigator: Christopher U. Jones         
John Muir Medical Center-Walnut Creek Suspended
Walnut Creek, California, United States, 94598
United States, Colorado
Memorial Hospital Central Recruiting
Colorado Springs, Colorado, United States, 80909
Contact: Anthony D. Elias    970-297-6150      
Principal Investigator: Anthony D. Elias         
Poudre Valley Hospital Recruiting
Fort Collins, Colorado, United States, 80524
Contact: Anthony D. Elias    970-297-6150      
Principal Investigator: Anthony D. Elias         
United States, Connecticut
Hartford Hospital Suspended
Hartford, Connecticut, United States, 06102
United States, Florida
Boca Raton Regional Hospital Recruiting
Boca Raton, Florida, United States, 33486
Contact: Sajeel A. Chowdhary    561-955-4800      
Principal Investigator: Sajeel A. Chowdhary         
University of Florida Suspended
Gainesville, Florida, United States, 32610
Baptist MD Anderson Cancer Center Suspended
Jacksonville, Florida, United States, 32207
University of Florida Health Science Center Recruiting
Jacksonville, Florida, United States, 32209
Contact: Ronny L. Rotondo    888-254-7581      
Principal Investigator: Ronny L. Rotondo         
Baptist Medical Center South Suspended
Jacksonville, Florida, United States, 32258
Moffitt Cancer Center Suspended
Tampa, Florida, United States, 33612
United States, Georgia
Emory University/Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Hui-Kuo G. Shu    404-778-1868      
Principal Investigator: Hui-Kuo G. Shu         
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Recruiting
Savannah, Georgia, United States, 31405
Contact: Howard A. Zaren    912-819-5704      
Principal Investigator: Howard A. Zaren         
United States, Idaho
Saint Alphonsus Cancer Care Center-Boise Recruiting
Boise, Idaho, United States, 83706
Contact: Samir Narayan    208-367-7954      
Principal Investigator: Samir Narayan         
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Timothy J. Kruser    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Timothy J. Kruser         
John H Stroger Jr Hospital of Cook County Recruiting
Chicago, Illinois, United States, 60612
Contact: Thomas E. Lad    312-864-6000      
Principal Investigator: Thomas E. Lad         
Rush University Medical Center Suspended
Chicago, Illinois, United States, 60612
University of Chicago Comprehensive Cancer Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Steven J. Chmura    312-355-3046      
Principal Investigator: Steven J. Chmura         
Decatur Memorial Hospital Recruiting
Decatur, Illinois, United States, 62526
Contact: James L. Wade    309-243-3605      
Principal Investigator: James L. Wade         
Northwestern Medicine Cancer Center Delnor Recruiting
Geneva, Illinois, United States, 60134
Contact: Vinai Gondi    630-315-1918    Claudine.Gamster@CadenceHealth.org   
Principal Investigator: Vinai Gondi         
UC Comprehensive Cancer Center at Silver Cross Recruiting
New Lenox, Illinois, United States, 60451
Contact: Steven J. Chmura    312-355-3046      
Principal Investigator: Steven J. Chmura         
Advocate Lutheran General Hospital Suspended
Park Ridge, Illinois, United States, 60068
OSF Saint Francis Medical Center Recruiting
Peoria, Illinois, United States, 61637
Contact: James L. Wade    309-243-3605      
Principal Investigator: James L. Wade         
Memorial Medical Center Suspended
Springfield, Illinois, United States, 62781
Northwestern Medicine Cancer Center Warrenville Recruiting
Warrenville, Illinois, United States, 60555
Contact: Vinai Gondi    630-315-1918    Claudine.Gamster@CadenceHealth.org   
Principal Investigator: Vinai Gondi         
United States, Indiana
Radiation Oncology Associates PC Recruiting
Fort Wayne, Indiana, United States, 46804
Contact: Brian K. Chang    260-373-8888    parkviewresearch@parkview.com   
Principal Investigator: Brian K. Chang         
Parkview Hospital Randallia Recruiting
Fort Wayne, Indiana, United States, 46805
Contact: Brian K. Chang    260-373-8888    parkviewresearch@parkview.com   
Principal Investigator: Brian K. Chang         
IU Health Methodist Hospital Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Kevin P. McMullen    317-962-5731      
Principal Investigator: Kevin P. McMullen         
Community Cancer Center East Suspended
Indianapolis, Indiana, United States, 46219
Community Cancer Center South Suspended
Indianapolis, Indiana, United States, 46227
Community Cancer Center North Suspended
Indianapolis, Indiana, United States, 46256
IU Health Ball Memorial Hospital Suspended
Muncie, Indiana, United States, 47303
United States, Iowa
Mercy Hospital Suspended
Cedar Rapids, Iowa, United States, 52403
Iowa Methodist Medical Center Suspended
Des Moines, Iowa, United States, 50309
United States, Kansas
University of Kansas Cancer Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
University of Kansas Cancer Center-Overland Park Recruiting
Overland Park, Kansas, United States, 66210
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
United States, Kentucky
Norton Hospital Pavilion and Medical Campus Suspended
Louisville, Kentucky, United States, 40202
United States, Louisiana
Ochsner Medical Center Jefferson Suspended
New Orleans, Louisiana, United States, 70121
United States, Maryland
Maryland Proton Treatment Center Recruiting
Baltimore, Maryland, United States, 21201
Contact: Mark V. Mishra    800-888-8823      
Principal Investigator: Mark V. Mishra         
University of Maryland/Greenebaum Cancer Center Recruiting
Baltimore, Maryland, United States, 21201
Contact: Mark V. Mishra    800-888-8823      
Principal Investigator: Mark V. Mishra         
Upper Chesapeake Medical Center Recruiting
Bel Air, Maryland, United States, 21014
Contact: Mark V. Mishra    800-888-8823      
Principal Investigator: Mark V. Mishra         
Central Maryland Radiation Oncology in Howard County Recruiting
Columbia, Maryland, United States, 21044
Contact: Mark V. Mishra    800-888-8823      
Principal Investigator: Mark V. Mishra         
Tate Cancer Center Recruiting
Glen Burnie, Maryland, United States, 21061
Contact: Mark V. Mishra    800-888-8823      
Principal Investigator: Mark V. Mishra         
United States, Massachusetts
Tufts Medical Center Recruiting
Boston, Massachusetts, United States, 02111
Contact: John E. Mignano    617-636-5000    ContactUsCancerCenter@TuftsMedicalCenter.org   
Principal Investigator: John E. Mignano         
Massachusetts General Hospital Cancer Center Recruiting
Boston, Massachusetts, United States, 02114
Contact: Helen A. Shih    877-726-5130      
Principal Investigator: Helen A. Shih         
Boston Medical Center Suspended
Boston, Massachusetts, United States, 02118
Mass General/North Shore Cancer Center Recruiting
Danvers, Massachusetts, United States, 01923
Contact: Helen A. Shih    877-726-5130      
Principal Investigator: Helen A. Shih         
Lowell General Hospital Suspended
Lowell, Massachusetts, United States, 01854
United States, Michigan
Saint Joseph Mercy Hospital Recruiting
Ann Arbor, Michigan, United States, 48106-0995
Contact: Samir Narayan    208-367-7954      
Principal Investigator: Samir Narayan         
University of Michigan Comprehensive Cancer Center Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Daniel E. Spratt    800-865-1125      
Principal Investigator: Daniel E. Spratt         
Henry Ford Hospital Suspended
Detroit, Michigan, United States, 48202
McLaren Cancer Institute-Flint Suspended
Flint, Michigan, United States, 48532
Mercy Health Saint Mary's Suspended
Grand Rapids, Michigan, United States, 49503
Spectrum Health at Butterworth Campus Suspended
Grand Rapids, Michigan, United States, 49503
West Michigan Cancer Center Suspended
Kalamazoo, Michigan, United States, 49007
McLaren Cancer Institute-Lapeer Region Suspended
Lapeer, Michigan, United States, 48446
Saint Mary Mercy Hospital Recruiting
Livonia, Michigan, United States, 48154
Contact: Samir Narayan    208-367-7954      
Principal Investigator: Samir Narayan         
McLaren Cancer Institute-Macomb Suspended
Mount Clemens, Michigan, United States, 48043
McLaren Cancer Institute-Central Michigan Suspended
Mount Pleasant, Michigan, United States, 48858
McLaren Cancer Institute-Owosso Suspended
Owosso, Michigan, United States, 48867
McLaren Cancer Institute-Northern Michigan Suspended
Petoskey, Michigan, United States, 49770
Saint Joseph Mercy Oakland Recruiting
Pontiac, Michigan, United States, 48341
Contact: Samir Narayan    208-367-7954      
Principal Investigator: Samir Narayan         
Lakeland Hospital Suspended
Saint Joseph, Michigan, United States, 49085
United States, Minnesota
Sanford Clinic North-Bemidgi Recruiting
Bemidji, Minnesota, United States, 56601
Contact: Preston D. Steen    712-252-0088      
Principal Investigator: Preston D. Steen         
Saint Luke's Hospital of Duluth Recruiting
Duluth, Minnesota, United States, 55805
Contact: Steven R. Bonin    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Steven R. Bonin         
Coborn Cancer Center at Saint Cloud Hospital Recruiting
Saint Cloud, Minnesota, United States, 56303
Contact: Donald J. Jurgens    877-229-4907      
Principal Investigator: Donald J. Jurgens         
Regions Hospital Suspended
Saint Paul, Minnesota, United States, 55101
United States, Mississippi
University of Mississippi Medical Center Suspended
Jackson, Mississippi, United States, 39216
United States, Missouri
North Kansas City Hospital Recruiting
Kansas City, Missouri, United States, 64116
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
The University of Kansas Cancer Center-North Recruiting
Kansas City, Missouri, United States, 64154
Contact: Joshua M. Mammen    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Joshua M. Mammen         
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Jiayi Huang    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Jiayi Huang         
United States, Montana
Billings Clinic Cancer Center Suspended
Billings, Montana, United States, 59101
United States, Nevada
Renown Regional Medical Center Recruiting
Reno, Nevada, United States, 89502
Contact: John A. Ellerton    805-474-9143      
Principal Investigator: John A. Ellerton         
Saint Mary's Regional Medical Center Recruiting
Reno, Nevada, United States, 89503
Contact: John A. Ellerton    805-474-9143      
Principal Investigator: John A. Ellerton         
United States, New Hampshire
Dartmouth Hitchcock Medical Center Suspended
Lebanon, New Hampshire, United States, 03756
United States, New Jersey
Memorial Sloan Kettering Basking Ridge Recruiting
Basking Ridge, New Jersey, United States, 07920
Contact: Mariza Daras    212-639-7202      
Principal Investigator: Mariza Daras         
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Atif J. Khan    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Atif J. Khan         
Rutgers Cancer Institute of New Jersey Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Atif J. Khan    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Atif J. Khan         
Capital Health Medical Center-Hopewell Recruiting
Pennington, New Jersey, United States, 08534
Contact: Shirnett K. Williamson    800-255-3440      
Principal Investigator: Shirnett K. Williamson         
ProCure Proton Therapy Center-Somerset Suspended
Somerset, New Jersey, United States, 08873
Virtua Voorhees Suspended
Voorhees, New Jersey, United States, 08043
United States, New York
New York-Presbyterian/Brooklyn Methodist Hospital Recruiting
Brooklyn, New York, United States, 11215
Contact: Sameer Rafla-Demetrious    718-780-3677    Adg9003@nyp.org   
Principal Investigator: Sameer Rafla-Demetrious         
Memorial Sloan Kettering Commack Recruiting
Commack, New York, United States, 11725
Contact: Mariza Daras    212-639-7202      
Principal Investigator: Mariza Daras         
Memorial Sloan Kettering Westchester Recruiting
Harrison, New York, United States, 10604
Contact: Mariza Daras    212-639-7202      
Principal Investigator: Mariza Daras         
Northwell Health/Center for Advanced Medicine Suspended
New Hyde Park, New York, United States, 11040
Columbia University/Herbert Irving Cancer Center Suspended
New York, New York, United States, 10032
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Mariza Daras    212-639-7202      
Principal Investigator: Mariza Daras         
Montefiore Medical Center - Moses Campus Suspended
The Bronx, New York, United States, 10467-2490
United States, North Carolina
Mission Hospital-Memorial Campus Recruiting
Asheville, North Carolina, United States, 28801
Contact: Christopher H. Chay    828-213-4150      
Principal Investigator: Christopher H. Chay         
Novant Health Forsyth Medical Center Suspended
Winston-Salem, North Carolina, United States, 27103
Wake Forest University Health Sciences Suspended
Winston-Salem, North Carolina, United States, 27157
United States, North Dakota
Sanford Bismarck Medical Center Recruiting
Bismarck, North Dakota, United States, 58501
Contact: Preston D. Steen    712-252-0088      
Principal Investigator: Preston D. Steen         
Roger Maris Cancer Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Preston D. Steen    712-252-0088      
Principal Investigator: Preston D. Steen         
United States, Ohio
Akron General Medical Center Recruiting
Akron, Ohio, United States, 44307
Contact: Mitchel L. Fromm    330-344-6348      
Principal Investigator: Mitchel L. Fromm         
UHHS-Chagrin Highlands Medical Center Recruiting
Beachwood, Ohio, United States, 44122
Contact: Mitchell Machtay    800-641-2422      
Principal Investigator: Mitchell Machtay         
Geaugra Hospital Recruiting
Chardon, Ohio, United States, 44024
Contact: Mitchell Machtay    800-641-2422      
Principal Investigator: Mitchell Machtay         
University of Cincinnati/Barrett Cancer Center Recruiting
Cincinnati, Ohio, United States, 45219
Contact: Kevin P. Redmond    513-558-4553    uchealthnews@uc.edu   
Principal Investigator: Kevin P. Redmond         
Case Western Reserve University Recruiting
Cleveland, Ohio, United States, 44106
Contact: Mitchell Machtay    800-641-2422      
Principal Investigator: Mitchell Machtay         
Cleveland Clinic Cancer Center/Fairview Hospital Recruiting
Cleveland, Ohio, United States, 44111
Contact: Samuel T. Chao    866-223-8100      
Principal Investigator: Samuel T. Chao         
Cleveland Clinic Foundation Recruiting
Cleveland, Ohio, United States, 44195
Contact: Samuel T. Chao    866-223-8100      
Principal Investigator: Samuel T. Chao         
Ohio State University Comprehensive Cancer Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Arnab Chakravarti    800-293-5066    Jamesline@osumc.edu   
Principal Investigator: Arnab Chakravarti         
Riverside Methodist Hospital Suspended
Columbus, Ohio, United States, 43214
Mercy Cancer Center-Elyria Recruiting
Elyria, Ohio, United States, 44035
Contact: Mitchell Machtay    800-641-2422      
Principal Investigator: Mitchell Machtay         
Cleveland Clinic Cancer Center Independence Recruiting
Independence, Ohio, United States, 44131
Contact: Samuel T. Chao    866-223-8100      
Principal Investigator: Samuel T. Chao         
Hillcrest Hospital Cancer Center Recruiting
Mayfield Heights, Ohio, United States, 44124
Contact: Samuel T. Chao    866-223-8100      
Principal Investigator: Samuel T. Chao         
Lake University Ireland Cancer Center Recruiting
Mentor, Ohio, United States, 44060
Contact: Mitchell Machtay    800-641-2422      
Principal Investigator: Mitchell Machtay         
Southwest General Health Center Ireland Cancer Center Recruiting
Middleburg Heights, Ohio, United States, 44130
Contact: Mitchell Machtay    800-641-2422      
Principal Investigator: Mitchell Machtay         
University Hospitals Parma Medical Center Recruiting
Parma, Ohio, United States, 44129
Contact: Mitchell Machtay    800-641-2422      
Principal Investigator: Mitchell Machtay         
Ireland Cancer Center at Firelands Regional Medical Center Recruiting
Sandusky, Ohio, United States, 44870
Contact: Mitchell Machtay    800-641-2422      
Principal Investigator: Mitchell Machtay         
North Coast Cancer Care Recruiting
Sandusky, Ohio, United States, 44870
Contact: Samuel T. Chao    866-223-8100      
Principal Investigator: Samuel T. Chao         
Cleveland Clinic Cancer Center Strongsville Recruiting
Strongsville, Ohio, United States, 44136
Contact: Samuel T. Chao    866-223-8100      
Principal Investigator: Samuel T. Chao         
University of Toledo Recruiting
Toledo, Ohio, United States, 43614
Contact: Krishna Reddy    419-383-6583      
Principal Investigator: Krishna Reddy         
University Pointe Recruiting
West Chester, Ohio, United States, 45069
Contact: Kevin P. Redmond    513-558-4553    uchealthnews@uc.edu   
Principal Investigator: Kevin P. Redmond         
UHHS-Westlake Medical Center Recruiting
Westlake, Ohio, United States, 44145
Contact: Mitchell Machtay    800-641-2422      
Principal Investigator: Mitchell Machtay         
Cleveland Clinic Wooster Family Health and Surgery Center Recruiting
Wooster, Ohio, United States, 44691
Contact: Samuel T. Chao    866-223-8100      
Principal Investigator: Samuel T. Chao         
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Terence S. Herman    405-271-8777    ou-clinical-trials@ouhsc.edu   
Principal Investigator: Terence S. Herman         
United States, Oregon
Willamette Valley Cancer Center Suspended
Eugene, Oregon, United States, 97401
Legacy Mount Hood Medical Center Suspended
Gresham, Oregon, United States, 97030
Legacy Good Samaritan Hospital and Medical Center Recruiting
Portland, Oregon, United States, 97210
Contact: Andrew Y. Kee    855-776-0015      
Principal Investigator: Andrew Y. Kee         
United States, Pennsylvania
Saint Luke's University Hospital-Bethlehem Campus Recruiting
Bethlehem, Pennsylvania, United States, 18015
Contact: Nimisha Deb    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Nimisha Deb         
Northeast Radiation Oncology Center Recruiting
Dunmore, Pennsylvania, United States, 18512
Contact: Wenyin Shi    215-955-6084      
Principal Investigator: Wenyin Shi         
Adams Cancer Center Recruiting
Gettysburg, Pennsylvania, United States, 17325
Contact: Amit B. Shah    877-441-7957      
Principal Investigator: Amit B. Shah         
PinnacleHealth Cancer Center-Community Campus Recruiting
Harrisburg, Pennsylvania, United States, 17109
Contact: David C. Weksberg    717-724-6765    klitchfield@PINNACLEHEALTH.org   
Principal Investigator: David C. Weksberg         
University of Pennsylvania/Abramson Cancer Center Suspended
Philadelphia, Pennsylvania, United States, 19104
Thomas Jefferson University Hospital Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Wenyin Shi    215-955-6084      
Principal Investigator: Wenyin Shi         
Aria Health-Torresdale Campus Recruiting
Philadelphia, Pennsylvania, United States, 19114
Contact: Wenyin Shi    215-955-6084      
Principal Investigator: Wenyin Shi         
Reading Hospital Recruiting
West Reading, Pennsylvania, United States, 19611
Contact: Terrence P. Cescon    610-988-9323      
Principal Investigator: Terrence P. Cescon         
WellSpan Health-York Cancer Center Recruiting
York, Pennsylvania, United States, 17403
Contact: Amit B. Shah    877-441-7957      
Principal Investigator: Amit B. Shah         
United States, South Carolina
Medical University of South Carolina Suspended
Charleston, South Carolina, United States, 29425
Greenville Health System Cancer Institute-Faris Recruiting
Greenville, South Carolina, United States, 29605
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
Greenville Health System Cancer Institute-Eastside Recruiting
Greenville, South Carolina, United States, 29615
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
Self Regional Healthcare Suspended
Greenwood, South Carolina, United States, 29646
Greenville Health System Cancer Institute-Greer Recruiting
Greer, South Carolina, United States, 29650
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
Greenville Health System Cancer Institute-Seneca Recruiting
Seneca, South Carolina, United States, 29672
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
Greenville Health System Cancer Institute-Spartanburg Recruiting
Spartanburg, South Carolina, United States, 29307
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
United States, South Dakota
Sanford USD Medical Center - Sioux Falls Recruiting
Sioux Falls, South Dakota, United States, 57117-5134
Contact: Preston D. Steen    712-252-0088      
Principal Investigator: Preston D. Steen         
United States, Tennessee
Tennessee Cancer Specialists-Dowell Springs Recruiting
Knoxville, Tennessee, United States, 37909
Contact: J. B. Wilkinson    865-244-3209      
Principal Investigator: J. B. Wilkinson         
United States, Texas
Dell Seton Medical Center at The University of Texas Suspended
Austin, Texas, United States, 78701
Austin Cancer Centers-Central Austin Suspended
Austin, Texas, United States, 78702
Texas Oncology-Austin Midtown Recruiting
Austin, Texas, United States, 78705
Contact: Vivek S. Kavadi    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Vivek S. Kavadi         
Texas Oncology - Central Austin Cancer Center Recruiting
Austin, Texas, United States, 78731
Contact: Vivek S. Kavadi    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Vivek S. Kavadi         
Texas Oncology - South Austin Cancer Center Recruiting
Austin, Texas, United States, 78745
Contact: Vivek S. Kavadi    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Vivek S. Kavadi         
Austin Cancer Centers-North Suspended
Austin, Texas, United States, 78758
UT Southwestern/Simmons Cancer Center-Dallas Recruiting
Dallas, Texas, United States, 75390
Contact: Robert D. Timmerman    214-590-5582      
Principal Investigator: Robert D. Timmerman         
Texas Oncology-Flower Mound Recruiting
Flower Mound, Texas, United States, 75028
Contact: Vivek S. Kavadi    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Vivek S. Kavadi         
The Klabzuba Cancer Center Suspended
Fort Worth, Texas, United States, 76104
University of Texas Medical Branch Suspended
Galveston, Texas, United States, 77555-0565
Memorial Hermann Memorial City Medical Center Suspended
Houston, Texas, United States, 77024
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Andrew J. Bishop    713-792-3245      
Principal Investigator: Andrew J. Bishop         
UTMB Cancer Center at Victory Lakes Suspended
League City, Texas, United States, 77573
Covenant Medical Center-Lakeside Recruiting
Lubbock, Texas, United States, 79410
Contact: Paul J. Anderson    806-725-8000    jaccresearch@covhs.org   
Principal Investigator: Paul J. Anderson         
Texas Oncology-Seton Williamson Suspended
Round Rock, Texas, United States, 78665
Texas Oncology - Round Rock Cancer Center Recruiting
Round Rock, Texas, United States, 78681
Contact: Vivek S. Kavadi    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Vivek S. Kavadi         
University of Texas Health Science Center at San Antonio Recruiting
San Antonio, Texas, United States, 78229
Contact: Richard L. Crownover    210-450-3800    CTO@uthscsa.edu   
Principal Investigator: Richard L. Crownover         
Texas Cancer Center-Sherman Recruiting
Sherman, Texas, United States, 75090
Contact: Vivek S. Kavadi    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Vivek S. Kavadi         
Texas Oncology Cancer Center Sugar Land Suspended
Sugar Land, Texas, United States, 77479
Tyler Cancer Center Recruiting
Tyler, Texas, United States, 75702
Contact: Vivek S. Kavadi    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Vivek S. Kavadi         
United States, Utah
Logan Regional Hospital Suspended
Logan, Utah, United States, 84321
Intermountain Medical Center Suspended
Murray, Utah, United States, 84107
McKay-Dee Hospital Center Suspended
Ogden, Utah, United States, 84403
Utah Valley Regional Medical Center Suspended
Provo, Utah, United States, 84604
Dixie Medical Center Regional Cancer Center Suspended
Saint George, Utah, United States, 84770
Huntsman Cancer Institute/University of Utah Recruiting
Salt Lake City, Utah, United States, 84112
Contact: Dennis C. Shrieve    801-581-4477    clinical.trials@hci.utah.edu   
Principal Investigator: Dennis C. Shrieve         
United States, Vermont
Central Vermont Medical Center/National Life Cancer Treatment Recruiting
Berlin Corners, Vermont, United States, 05602
Contact: Carl J. Nelson    802-656-4101      
Principal Investigator: Carl J. Nelson         
University of Vermont Medical Center Recruiting
Burlington, Vermont, United States, 05401
Contact: Carl J. Nelson    802-656-4101      
Principal Investigator: Carl J. Nelson         
Norris Cotton Cancer Center-North Suspended
Saint Johnsbury, Vermont, United States, 05819
United States, Virginia
Virginia Commonwealth University/Massey Cancer Center Suspended
Richmond, Virginia, United States, 23298
United States, Washington
ProCure Proton Therapy Center-Seattle Suspended
Seattle, Washington, United States, 98133
Seattle Cancer Care Alliance at Northwest Hospital Recruiting
Seattle, Washington, United States, 98133
Contact: Lia M. Halasz    800-422-6237      
Principal Investigator: Lia M. Halasz         
University of Washington Medical Center Recruiting
Seattle, Washington, United States, 98195
Contact: Lia M. Halasz    800-422-6237      
Principal Investigator: Lia M. Halasz         
Compass Oncology Vancouver Recruiting
Vancouver, Washington, United States, 98684
Contact: Vivek S. Kavadi    913-945-7552    ctnursenav@kumc.edu   
Principal Investigator: Vivek S. Kavadi         
Legacy Salmon Creek Hospital Suspended
Vancouver, Washington, United States, 98686
United States, West Virginia
Wheeling Hospital/Schiffler Cancer Center Recruiting
Wheeling, West Virginia, United States, 26003
Contact: Jondavid Pollock    304-243-6442      
Principal Investigator: Jondavid Pollock         
United States, Wisconsin
Langlade Hospital and Cancer Center Suspended
Antigo, Wisconsin, United States, 54409
Gundersen Lutheran Medical Center Recruiting
La Crosse, Wisconsin, United States, 54601
Contact: Collin D. Driscoll    608-775-2385    cancerctr@gundersenhealth.org   
Principal Investigator: Collin D. Driscoll         
University of Wisconsin Hospital and Clinics Suspended
Madison, Wisconsin, United States, 53792
Community Memorial Hospital Recruiting
Menomonee Falls, Wisconsin, United States, 53051
Contact: Joseph A. Bovi    414-805-4380      
Principal Investigator: Joseph A. Bovi         
Froedtert and the Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Joseph A. Bovi    414-805-4380      
Principal Investigator: Joseph A. Bovi         
UW Cancer Center at ProHealth Care Suspended
Waukesha, Wisconsin, United States, 53188
Aspirus Regional Cancer Center Suspended
Wausau, Wisconsin, United States, 54401
Aspirus UW Cancer Center Recruiting
Wisconsin Rapids, Wisconsin, United States, 54494
Contact: Darryl R. Barton    877-405-6866      
Principal Investigator: Darryl R. Barton         
Canada, British Columbia
BCCA-Vancouver Island Cancer Centre Recruiting
Victoria, British Columbia, Canada, V8R 6V5
Contact: Abraham S. Alexander    604-877-6010      
Principal Investigator: Abraham S. Alexander         
Canada, Ontario
Ottawa Hospital and Cancer Center-General Campus Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Jean-Michel Caudrelier    613-761-4395      
Principal Investigator: Jean-Michel Caudrelier         
Windsor Regional Cancer Centre Suspended
Windsor, Ontario, Canada, N8W 2X3
Canada, Quebec
CHUM - Hopital Notre-Dame Recruiting
Montreal, Quebec, Canada, H2L 4M1
Contact: Jean-Paul Bahary    514-890-8000 ext 14788    marie-josee.samson.chum@ssss.gouv.qc.ca   
Principal Investigator: Jean-Paul Bahary         
McGill University Department of Oncology Suspended
Montreal, Quebec, Canada, H2W 1S6
The Research Institute of the McGill University Health Centre (MUHC) Recruiting
Montreal, Quebec, Canada, H3H 2R9
Contact: Valerie Panet-Raymond    514-934-1934 ext 48354    evelyn.ortega@muhc.mcgill.ca   
Principal Investigator: Valerie Panet-Raymond         
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ) Suspended
Quebec City, Quebec, Canada, G1R 2J6
Canada, Saskatchewan
Saskatoon Cancer Centre Suspended
Saskatoon, Saskatchewan, Canada, S7N 4H4
Sponsors and Collaborators
NRG Oncology
National Cancer Institute (NCI)
Radiation Therapy Oncology Group
Investigators
Principal Investigator: Minesh Mehta NRG Oncology
  More Information

Responsible Party: NRG Oncology
ClinicalTrials.gov Identifier: NCT02179086     History of Changes
Obsolete Identifiers: NCT02163135
Other Study ID Numbers: NRG-BN001
NCI-2014-01072 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
NRG-BN001 ( Other Identifier: NRG Oncology )
NRG-BN001 ( Other Identifier: CTEP )
U10CA180868 ( U.S. NIH Grant/Contract )
Study First Received: June 27, 2014
Last Updated: September 6, 2017

Additional relevant MeSH terms:
Glioblastoma
Gliosarcoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Temozolomide
Dacarbazine
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents

ClinicalTrials.gov processed this record on September 21, 2017